In this article, we will look at the 7 Fastest Growing European Stocks to Invest In.
European stocks are getting a closer look again, and not only because investors want to diversify away from a crowded U.S. trade. The more interesting shift is that the region is starting to look better on its own terms. Fidelity says, “The case for Europe has strengthened considerably,” adding that “Falling inflation, lower interest rates, and fiscal support all provide a supportive backdrop for corporate investment and consumer confidence.” Faster-growing companies have a better setup when financing conditions are easing, and business confidence is improving. Fidelity also makes an important distinction, saying “European companies should not be seen as proxies for the region’s economy. They are global businesses with resilient balance sheets and proven growth profiles.” The argument is not simply that Europe is recovering. It is that many European-listed companies can still grow faster than the region.
Schroders adds a more immediate market angle. In its February 2026 fund update, the firm says “European shares gained in February, benefitting from signs of an economic pick-up in the region and ongoing rotation away from US shares.” That suggests investors are already beginning to reposition as Europe’s backdrop improves. Schroders also notes that “Value remains extremely attractively priced,” with “international Value stocks trade below long run multiples, and UK valuations are at historically low levels.” When a market is still priced conservatively, but the growth picture is improving, faster-growing companies in that market can stand out even more.
Taken together, these reports suggest Europe is no longer just a catch-up or valuation story. It is increasingly a region where improving macro conditions, stronger investor flows, and globally exposed businesses are creating room for growth stocks to get more attention. With that in mind, we will look at the 7 Fastest-Growing European Stocks to Invest In.
Our Methodology
We used the Finviz screener to identify European stocks that have achieved more than 50% sales growth over the past three years. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7. Ascendis Pharma A/S (NASDAQ:ASND)
On March 17, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced positive Week 52 topline results from the Phase 2 New InsiGHTS trial evaluating once-weekly TransCon hGH against daily somatropin in prepubertal children with Turner syndrome. At Week 52, annualized height velocity was similar between the two groups, with an LS mean of 9.05 cm/year for TransCon hGH-treated children versus 9.04 cm/year for daily somatropin. The company also said TransCon hGH showed a safety and tolerability profile similar to daily somatropin through follow-up of up to 143 weeks, with adverse events reported as mild to moderate and no discontinuations due to adverse events.
On March 16, 2026, Jefferies assumed coverage of Ascendis Pharma A/S (NASDAQ:ASND) with a Buy rating and a $290 price target, describing the company as a “two-engine growth story” with Yorvipath on a “hot growth trajectory” and Yuviwel positioned to “disrupt” achondroplasia in the near term.
On the same day, the company announced new data from its pivotal ApproaCH trial showing that children with achondroplasia treated with once-weekly TransCon CNP maintained growth improvements through Week 104, with further gains in body proportionality during the second year of treatment. Ascendis said TransCon CNP, approved by the U.S. FDA in February 2026 under the trade name YUVIWEL, remains under review by the European Medicines Agency, with a decision expected in the fourth quarter of 2026.
Ascendis Pharma A/S (NASDAQ:ASND) develops TransCon-based therapies for unmet medical needs.
6. BeOne Medicines AG (NASDAQ:ONC)
On March 26, 2026, Wolfe Research analyst Kalpit Patel initiated coverage on BeOne Medicines AG (NASDAQ:ONC) with an Outperform rating and a $340 price target, saying the company runs one of the broadest development programs in biotech. The analyst highlighted Brukinsa as a “category-leading flagship drug” alongside a “credible” pipeline, adding that concerns around fixed-duration therapies appear “overdone” and could present a buying opportunity.
On March 23, 2026, BeOne Medicines AG (NASDAQ:ONC) received orphan drug designation from the FDA for its hepatocellular carcinoma treatment.
On March 16, 2026, Jefferies analyst Faisal Khurshid downgraded BeOne Medicines AG (NASDAQ:ONC) to Hold from Buy with a $290 price target, down from $420, stating that while Brukinsa remains a leading hematology asset, the stock “is not mispriced” at current levels. The firm added that leadership in chronic lymphocytic leukemia is already reflected, with future growth drivers expected to play out more gradually.
BeOne Medicines AG (NASDAQ:ONC) develops oncology treatments across global markets.
While we acknowledge the potential of ONC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ONC and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Fastest Growing European Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center